These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 19933411)

  • 1. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study".
    George J
    Circ Heart Fail; 2010 May; 3(3):e10; author reply e14. PubMed ID: 20484184
    [No Abstract]   [Full Text] [Related]  

  • 3. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
    Anker SD; Doehner W; Rauchhaus M; Sharma R; Francis D; Knosalla C; Davos CH; Cicoira M; Shamim W; Kemp M; Segal R; Osterziel KJ; Leyva F; Hetzer R; Ponikowski P; Coats AJ
    Circulation; 2003 Apr; 107(15):1991-7. PubMed ID: 12707250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
    Fujimori S; Ooyama K; Ooyama H; Moromizato H
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure.
    Jankowska EA; Ponikowska B; Majda J; Zymlinski R; Trzaska M; Reczuch K; Borodulin-Nadzieja L; Banasiak W; Ponikowski P
    Int J Cardiol; 2007 Feb; 115(2):151-5. PubMed ID: 16782216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study.
    Cingolani HE; Plastino JA; Escudero EM; Mangal B; Brown J; Pérez NG
    J Card Fail; 2006 Sep; 12(7):491-8. PubMed ID: 16952781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?
    Duan X; Ling F
    Med Hypotheses; 2008; 70(3):578-81. PubMed ID: 17689199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
    Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
    Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.
    Doehner W; Rauchhaus M; Florea VG; Sharma R; Bolger AP; Davos CH; Coats AJ; Anker SD
    Am Heart J; 2001 May; 141(5):792-9. PubMed ID: 11320368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
    Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperuricemia in acute heart failure. More than a simple spectator?
    Alimonda AL; Núñez J; Núñez E; Husser O; Sanchis J; Bodí V; Miñana G; Robles R; Mainar L; Merlos P; Darmofal H; Llácer A
    Eur J Intern Med; 2009 Jan; 20(1):74-9. PubMed ID: 19237097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
    Ohta Y; Ishizuka A; Arima H; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
    Hypertens Res; 2017 Mar; 40(3):259-263. PubMed ID: 27760998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
    Harzand A; Tamariz L; Hare JM
    Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure.
    Niizeki T; Takeishi Y; Arimoto T; Okuyama H; Nozaki N; Hirono O; Tsunoda Y; Watanabe T; Nitobe J; Miyashita T; Takahashi H; Koyama Y; Kubota I
    J Cardiol; 2006 May; 47(5):219-28. PubMed ID: 16764328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.